Dr. Fernando O. Recio, MD

Dr. Recio practices at South Florida Center for Gynecologic Oncology P A in Boca Raton, Florida.

Dr. Recio's NPI, 1245227818, was assigned on September 29, 2005. Dr. Recio graduated from Universidad Central del Caribe School of Medicine in 1984. Dr. Recio holds Florida license ME79470.

Dr. Recio's primary practice is South Florida Center for Gynecologic Oncology P A, at 6200 N Federal Hwy, Boca Raton, FL 33487 in Palm Beach County. The practice phone is (561) 997-8991.

Dr. Recio's primary practice is South Florida Center for Gynecologic Oncology P A in Boca Raton, Florida. Dr. Recio is also affiliated with Boca Raton Regional Hospital. The medical group on file is South Florida Center for Gynecologic Oncology. Dmand AI also links Dr. Recio to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Recio practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Recio's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Recio is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Recio's licenses on file in 5 states: Florida, New York, West Virginia, Pennsylvania and Ohio.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Recio treats.

CMS data shows 52,619 Medicare services from Dr. Recio across 34 procedure codes in 2024, for 553 Medicare patients. Medicare paid $792,717 for them.

CMS counts 553 Medicare patients who saw Dr. Recio in 2024. The largest group is 65 to 74, with 234 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.29, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Recio's median patient age at 70, with 98% women.

In 2024, Dr. Recio wrote 2,232 Medicare Part D claims for 498 patients. 90% of them were for generic drugs. CMS names the drug for 1,927 of them, across 38 drugs with 11 or more claims each, at $1,900,549 in total drug cost. In 2023, CMS named 1,857 claims across 38 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Recio for performance year 2024, reported individually. Dr. Recio accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 24 procedures of removal of the uterus by Dr. Recio, more than 95% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 35 papers to Dr. Recio, published from 2014 to 2025. 2014 was the busiest year, with 2. The most frequent topics are Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Cisplatin. Dr. Recio has published most often in Gynecol Oncol. Dr. Recio's most frequent co-authors are Robert W. Holloway, MD, Ahmad Awada, MD and Nathalie D. McKenzie, MD.

Dmand AI links Dr. Recio to 1 clinical trial. Conditions studied include Carcinoma, Ovarian Epithelial and Ovarian Neoplasms.

CMS Open Payments shows 416 general payments to Dr. Recio from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 41% of the total. Eisai Inc. paid the most, $17,900.

Dmand AI lists 2 awards for Dr. Recio, most recently CMS Stage 1 EHR in 2013.

Dr. Recio graduated from Universidad Central del Caribe School of Medicine in 1984. Dr. Recio is a member of American College of Obstetricians and Gynecologists and ACS.

Dr. Recio is in network with 10 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.